Healthcare provider profile · identity verified

Deborah A Learson, MD

Family Practice · NEWMARKET, NH · NPI 1154480549

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	294	89
Lisinopril	Lisinopril	243	69
Amlodipine Besylate	Amlodipine Besylate	201	55
Levothyroxine Sodium	Levothyroxine Sodium	183	52
Losartan Potassium	Losartan Potassium	151	47
Simvastatin	Simvastatin	119	34
Omeprazole	Omeprazole	116	38
Metoprolol Succinate	Metoprolol Succinate	111	31
Gabapentin	Gabapentin	97	32
Metformin Hcl Er	Metformin Hcl	88	31
Rosuvastatin Calcium	Rosuvastatin Calcium	85	27
Sertraline Hcl	Sertraline Hcl	81	22
Hydrochlorothiazide	Hydrochlorothiazide	72	21
Escitalopram Oxalate	Escitalopram Oxalate	63	18
Metformin Hcl	Metformin Hcl	61	15
Albuterol Sulfate Hfa	Albuterol Sulfate	60	33
Pantoprazole Sodium	Pantoprazole Sodium	59	17
Eliquis	Apixaban	58	14
Trazodone Hcl	Trazodone Hcl	56	19
Lorazepam	Lorazepam	54	16
Duloxetine Hcl	Duloxetine Hcl	53	16
Atenolol	Atenolol	51	13
Citalopram Hbr	Citalopram Hydrobromide	50	12
Zolpidem Tartrate	Zolpidem Tartrate	47	13
Fluoxetine Hcl	Fluoxetine Hcl	41	11
Montelukast Sodium	Montelukast Sodium	39	11
Furosemide	Furosemide	38	13
Donepezil Hcl	Donepezil Hcl	37	12
Metoprolol Tartrate	Metoprolol Tartrate	32	suppressed
Alendronate Sodium	Alendronate Sodium	31	suppressed
Ozempic	Semaglutide	29	suppressed
Warfarin Sodium	Warfarin Sodium	29	suppressed
Januvia	Sitagliptin Phosphate	28	suppressed
Valsartan	Valsartan	28	suppressed
Ibandronate Sodium	Ibandronate Sodium	27	suppressed
Bupropion Xl	Bupropion Hcl	26	suppressed
Famotidine	Famotidine	25	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	25	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	25	suppressed
Meloxicam	Meloxicam	25	suppressed
Prednisone	Prednisone	25	19
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	23	suppressed
Glipizide	Glipizide	22	suppressed
Pravastatin Sodium	Pravastatin Sodium	22	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Pregabalin	Pregabalin	20	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	20	suppressed
Jardiance	Empagliflozin	19	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Allopurinol	Allopurinol	18	suppressed
Alprazolam	Alprazolam	18	suppressed
Clopidogrel	Clopidogrel Bisulfate	18	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Synthroid	Levothyroxine Sodium	18	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Oxycodone Hcl	Oxycodone Hcl	17	suppressed
Terazosin Hcl	Terazosin Hcl	17	suppressed
Tramadol Hcl	Tramadol Hcl	17	suppressed
Valacyclovir	Valacyclovir Hcl	16	suppressed
Lovastatin	Lovastatin	15	suppressed
Midodrine Hcl	Midodrine Hcl	15	suppressed
Irbesartan	Irbesartan	14	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	14	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	13
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Carvedilol	Carvedilol	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Eszopiclone	Eszopiclone	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed
Potassium Chloride	Potassium Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error